Body Composition by Computed Tomography as a Predictor of Toxicity in Patients With Renal Cell Carcinoma Treated With Sunitinib

Definition and classification of cancer cachexia: an international consensus

2011 • 4,715 citations

Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study

2008 • 2,734 citations

Renal-Cell Carcinoma

1996 • 2,232 citations

A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care

2008 • 1,819 citations

Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study

2011 • 1,645 citations

Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment

2009 • 999 citations

Changes in Body Composition during Androgen Deprivation Therapy for Prostate Cancer

2002 • 640 citations

Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer

2009 • 622 citations

Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy Toxicity

2007 • 548 citations

Body composition in patients with non−small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis

2010 • 429 citations

Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma

2010 • 411 citations

Prediction of resting energy expenditure from fat-free mass and fat mass

1992 • 368 citations

Lean Body Mass as a Predictor of Drug Dosage

1994 • 290 citations

Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma

2012 • 284 citations

Association of Skeletal Muscle Wasting With Treatment With Sorafenib in Patients With Advanced Renal Cell Carcinoma: Results From a Placebo-Controlled Study

2010 • 273 citations

Body composition: Why, when and for who?

2012 • 220 citations

Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients

2013 • 216 citations

Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies

2013 • 200 citations

An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity

2010 • 152 citations

The Relationships between Body Composition and the Systemic Inflammatory Response in Patients with Primary Operable Colorectal Cancer

2012 • 149 citations

Flat-Fixed Dosing Versus Body Surface Area–Based Dosing of Anticancer Drugs in Adults: Does It Make a Difference?

2007 • 134 citations

Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity

2011 • 129 citations

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

2008 • 123 citations

Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation.

1998 • 123 citations

Body Composition Variation and Impact of Low Skeletal Muscle Mass in Patients With Advanced Medullary Thyroid Carcinoma Treated With Vandetanib: Results From a Placebo-Controlled Study

2013 • 97 citations

Determination of Height, Weight, Body Mass Index, and Body Surface Area with a Single Abdominal CT Image

2003 • 49 citations

Sorafenib and Sunitinib, Two Anticancer Drugs, Inhibit CYP3A4-Mediated and Activate CY3A5-Mediated Midazolam 1′-Hydroxylation

2011 • 48 citations

Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis

2012 • 37 citations

Loss of skeletal muscle in cancer biochemical mechanisms

2001 • 25 citations

Evaluation of treatment options for patients with advanced renal cell carcinoma: Assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology

2012 • 17 citations

Weight and body composition changes during R-CHOP chemotherapy in patients with non-Hodgkin's lymphoma and their impact on dose intensity and toxicity.

2010 • 14 citations